Full Year 2021 Product Sales

The following table provides the top 20 Innovative Medicines Division product net sales in 2021 as well as the change compared to 2020:

Brands
 
Net Sales
(USD m)
% change
(USD)
Business Franchise
 
Cosentyx 4,718 18% Immunology, Hepatology and Dermatology
Entresto 3,548 42% Cardiovascular, Renal and Metabolism
Gilenya 2,787 -7% Neuroscience
Lucentis 2,160 12% Ophthalmology
Tasigna 2,060 5% Hematology
Promacta/Revolade 2,016 16% Hematology
Tafinlar + Mekinist 1,693 10% Solid Tumor
Jakavi 1,595 19% Hematology
Xolair1 1,428 14% Respiratory and Allergy
Sandostatin 1,413 -2% Solid Tumor
Zolgensma 1,351 47% Neuroscience
Galvus Group 1,092 -9% Established Medicines
Ilaris 1,059 21% Immunology, Hepatology and Dermatology
Gleevec/Glivec 1,024 -14% Hematology
Afinitor/Votubia 938 -13% Solid Tumor
Kisqali 937 36% Solid Tumor
Exforge Group 901 -8% Established Medicines
Diovan Group 773 -23% Established Medicines
Kymriah 587 24% Hematology
Ultibro Group 584 -6% Respiratory and Allergy
  1. Net sales reflect Xolair sales for all indications.